众生药业
(002317)
| 流通市值：191.16亿 | | | 总市值：211.55亿 |
| 流通股本：7.68亿 | | | 总股本：8.50亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,468,004,093.45 | 1,000,420,115.22 | 624,239,320.67 | 2,522,737,619.7 |
| 营业收入 | 1,468,004,093.45 | 1,000,420,115.22 | 624,239,320.67 | 2,522,737,619.7 |
| 二、营业总成本 | 1,334,467,479.62 | 888,603,999.58 | 514,225,795.98 | 2,225,746,035.9 |
| 营业成本 | 656,682,617.53 | 436,930,790.14 | 266,632,302.08 | 1,107,007,576.85 |
| 税金及附加 | 13,233,397.29 | 8,782,465.83 | 6,086,212.43 | 20,257,110.33 |
| 销售费用 | 513,170,980.16 | 348,775,162.65 | 197,500,169.04 | 869,866,759.61 |
| 管理费用 | 102,346,746.25 | 66,753,701.68 | 30,343,563.04 | 142,855,933.54 |
| 研发费用 | 51,652,071.85 | 29,371,829.26 | 14,635,225.78 | 91,028,059.82 |
| 财务费用 | -2,618,333.46 | -2,009,949.98 | -971,676.39 | -5,269,404.25 |
| 其中:利息费用 | 1,339,210.32 | 751,976.94 | 378,303.73 | 4,996,927.17 |
| 其中:利息收入 | 3,435,941.95 | 2,318,052.46 | 969,703.22 | 8,861,662.58 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -25,182,313.66 | -23,943,057.03 | -13,168,866.19 | -19,489,239.27 |
| 加:投资收益 | 8,895,408.67 | 7,983,362.09 | 3,457,821.09 | 16,577,557.9 |
| 资产处置收益 | 9,935,713.51 | 6,187,070.22 | 3,924,528.3 | 6,049,345.32 |
| 资产减值损失(新) | 40,060,868.44 | -1,387,938.02 | -26,435.49 | -22,572,227.89 |
| 信用减值损失(新) | 9,476,433.75 | 4,394,013.81 | 42,490.6 | -8,145,202.19 |
| 其他收益 | 22,518,158.42 | 14,263,962.65 | 7,947,099.14 | 28,887,676.25 |
| 四、营业利润 | 199,240,882.96 | 119,313,529.36 | 112,190,162.14 | 298,299,493.92 |
| 加:营业外收入 | 5,624,485.43 | 5,618,198.32 | 5,555,765.06 | 1,240,188.83 |
| 减:营业外支出 | 2,221,066.74 | 1,333,276.72 | 53,590.83 | 2,953,849.23 |
| 五、利润总额 | 202,644,301.65 | 123,598,450.96 | 117,692,336.37 | 296,585,833.52 |
| 减:所得税费用 | 23,449,873.53 | 16,851,480.66 | 19,667,105.03 | 29,881,264.63 |
| 六、净利润 | 179,194,428.12 | 106,746,970.3 | 98,025,231.34 | 266,704,568.89 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 179,194,428.12 | 106,746,970.3 | 98,025,231.34 | 266,704,568.89 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 176,580,991.59 | 111,423,979.07 | 99,822,991.5 | 275,754,918.87 |
| 少数股东损益 | 2,613,436.53 | -4,677,008.77 | -1,797,760.16 | -9,050,349.98 |
| 扣除非经常损益后的净利润 | 183,899,431.71 | 120,783,851.89 | 102,671,532.63 | 281,056,460.86 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.21 | 0.13 | 0.12 | 0.33 |
| (二)稀释每股收益 | 0.21 | 0.13 | 0.12 | 0.33 |
| 八、其他综合收益 | -2,534,105.87 | -810,552.41 | -465,901.91 | -5,349,740.05 |
| 归属于母公司股东的其他综合收益 | -2,534,105.87 | -810,552.41 | -465,901.91 | -5,349,740.05 |
| 九、综合收益总额 | 176,660,322.25 | 105,936,417.89 | 97,559,329.43 | 261,354,828.84 |
| 归属于母公司股东的综合收益总额 | 174,046,885.72 | 110,613,426.66 | 99,357,089.59 | 270,405,178.82 |
| 归属于少数股东的综合收益总额 | 2,613,436.53 | -4,677,008.77 | -1,797,760.16 | -9,050,349.98 |
| 公告日期 | 2026-10-30 | 2026-08-25 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |